Middle Eastern plants show promiseMiddle Eastern Plants with Potent Cytotoxic Effect Against Lung Cancer Cells.
We screened 20 extracts from Middle Eastern plants to see how they affect lung cancer cells. Interestingly, 11 of these extracts showed promising results, demonstrating a strong cytotoxic effect. The most effective fractions showed their potential to induce cell death through apoptosis rather than necrosis.
While the results highlight the possible benefits of these plant extracts as supplementary options for lung cancer management, further investigation is needed to fully understand their impact and the safety for use in cancer treatment.
Read More
GSE and MTE show promise against lung cancerCombinations of grape seed procyanidin extract and milk thistle silymarin extract against lung cancer - The role of MiR-663a and FHIT.
We explored the effects of grape seed extract (GSE) and milk thistle extract (MTE) on lung cancer. Our study tested how these two extracts might work together to inhibit cancer cell growth in lab settings and in mice.
We found that when combined, GSE and MTE were effective in reducing tumor growth without causing toxicity. They helped raise levels of key tumor suppressors, which are important in fighting cancer.
Overall, this research encourages further investigation into using these natural extracts as potential treatments for lung cancer.
Read More
Potential NSCLC treatment candidateSilibinin Regulates Tumor Progression and Tumorsphere Formation by Suppressing PD-L1 Expression in Non-Small Cell Lung Cancer (NSCLC) Cells.
We investigated the potential of silibinin, a natural compound from milk thistle, in treating non-small cell lung cancer (NSCLC). Our study employed various assays to analyze how silibinin impacts cancer cell growth and migration.
We found that silibinin effectively inhibited the growth of NSCLC cells and suppressed important pathways linked to tumor progression. It worked by preventing tumor cells' ability to form new tumors and inhibited the expression of proteins associated with cancer growth.
Overall, silibinin shows promise as a candidate for both tumor immunotherapy and targeting cancer stem cells.
Read More
Silymarin inhibits lung cancer mobilityTherapeutic intervention of silymarin on the migration of non-small cell lung cancer cells is associated with the axis of multiple molecular targets including class 1 HDACs, ZEB1 expression, and restoration of miR-203 and E-cadherin expression.
We explored the effects of silymarin, a compound from the milk thistle plant, on the migration of non-small cell lung cancer (NSCLC) cells. In our study, we found that silymarin significantly inhibited cell movement in various NSCLC cell lines in a dose-dependent manner. This effect was linked to reductions in specific proteins that encourage cell movement, as well as an increase in tumor-suppressing microRNAs.
While promising, silymarin’s benefits in lung cancer treatment are still under investigation, and it may serve as a complementary treatment alongside conventional therapies.
Read More
Silibinin mitigates tumor growthSilibinin meglumine, a water-soluble form of milk thistle silymarin, is an orally active anti-cancer agent that impedes the epithelial-to-mesenchymal transition (EMT) in EGFR-mutant non-small-cell lung carcinoma cells.
We examined how a special form of milk thistle called silibinin meglumine could impact non-small-cell lung carcinoma (NSCLC). In our study, this formulation reduced tumor sizes in mice just as effectively as a popular treatment called gefitinib.
What's fascinating is that silibinin meglumine not only controlled tumor growth but also helped prevent tumors from returning in cases resistant to gefitinib. Additionally, it showed potential in blocking a process called epithelial-to-mesenchymal transition, which often contributes to treatment resistance. This non-toxic option could pave the way for future clinical trials combining it with existing therapies for lung cancer.
Read More